Abstract
Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.
| Original language | American English |
|---|---|
| Pages (from-to) | 786-804 |
| Number of pages | 19 |
| Journal | Nature Reviews Drug Discovery |
| Volume | 15 |
| Issue number | 11 |
| DOIs | |
| State | Published - 1 Nov 2016 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
